Bristol, Pharmasset To Study Oral HCV Regimen Together

Partnership to study Bristol's NS5A inhibitor with Pharmasset's polymerase inhibitor is the first cross-company collaboration to study two oral agents in hepatitis C.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet